Go Pro
→ Analyst nicknamed “The Prophet” issues new warning for America (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
$0.95
-0.2%		$1.14
$0.77
▼
$2.95
$4.89M1.45197,947 shs33,998 shs
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
$1.87
-3.9%		$1.86
$0.97
▼
$7.91
$5.54M2.281.38 million shs10,339 shs
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
$0.53
-15.4%		$1.08
$0.52
▼
$52.50
$1.22M3.521.97 million shs377,278 shs
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
$2.41
+9.3%		$2.64
$2.01
▼
$10.28
$5.70M1.38738,091 shs3,632 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
0.00%-16.67%-24.00%-12.84%-48.37%
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
0.00%-3.47%+5.41%-6.25%-52.09%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.00%+3.33%-53.31%-60.11%-98.61%
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
0.00%+0.70%-7.45%-3.14%-87.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
$0.95
-0.2%		$1.14
$0.77
▼
$2.95
$4.89M1.45197,947 shs33,998 shs
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
$1.87
-3.9%		$1.86
$0.97
▼
$7.91
$5.54M2.281.38 million shs10,339 shs
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
$0.53
-15.4%		$1.08
$0.52
▼
$52.50
$1.22M3.521.97 million shs377,278 shs
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
$2.41
+9.3%		$2.64
$2.01
▼
$10.28
$5.70M1.38738,091 shs3,632 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
0.00%-16.67%-24.00%-12.84%-48.37%
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
0.00%-3.47%+5.41%-6.25%-52.09%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
0.00%+3.33%-53.31%-60.11%-98.61%
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
0.00%+0.70%-7.45%-3.14%-87.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
1.00
SellN/AN/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
1.00
SellN/AN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
1.00
SellN/AN/A
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest PPCB, AQB, CDIO, and XTLB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/8/2026
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/28/2026
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/26/2026
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/12/2026
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/12/2026
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/8/2026
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/6/2026
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
$2.47M1.98N/AN/A($0.49) per share-1.94
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
$10K554.41N/AN/A$3.82 per share0.49
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/A$29.94 per shareN/A
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
$450K12.67N/AN/A($0.11) per share-21.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
-$18.49M-$0.82N/AN/AN/AN/A-147.07%-28.73%11/10/2026 (Estimated)
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
-$6.50M-$2.92N/AN/AN/A-43,133.33%-82.28%-76.03%11/6/2026 (Estimated)
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
-$18.86M-$24.25N/AN/AN/AN/A-151.28%-109.53%N/A
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
-$6.97M-$0.64N/AN/AN/AN/AN/AN/AN/A

Latest PPCB, AQB, CDIO, and XTLB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/25/2026Q4 2026
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/A$6.13N/A$6.13N/AN/A
8/7/2026Q2 2026
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
N/A-$0.51N/A-$0.51N/A$0.01 million
8/6/2026Q2 2026
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
N/A-$0.26N/A-$0.32N/AN/A
6/30/2026Q4 2025
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
N/A-$0.10N/A-$0.10N/A($0.26) million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
N/AN/AN/AN/AN/A
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
N/AN/AN/AN/AN/A
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/AN/AN/AN/AN/A
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
N/A
4.26
4.26
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
N/A
17.16
17.16
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/A
2.37
2.37
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
N/A
0.40
0.40

Institutional Ownership

CompanyInstitutional Ownership
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
8.92%
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
8.06%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
N/A
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
4.40%

Insider Ownership

CompanyInsider Ownership
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
1.02%
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
8.99%
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
28.67%
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
29.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
AquaBounty Technologies, Inc. stock logo
AQB
AquaBounty Technologies
1005.15 million5.10 millionNo Data
Cardio Diagnostics Holdings, Inc. stock logo
CDIO
Cardio Diagnostics
12.96 million2.69 millionNot Optionable
Propanc Biopharma Inc stock logo
PPCB
Propanc Biopharma
22.28 million1.63 millionNot Optionable
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
102.37 million1.68 millionNot Optionable

Recent News About These Companies

Critical Contrast: XTL Biopharmaceuticals (NASDAQ:XTLB) vs. Neuphoria Therapeutics (NASDAQ:NEUP)
September 25 at 4:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31048524
XTL Biopharmaceuticals Ltd. Sponsored ADR
July 8, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/XTLB
XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-Hours
July 1, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/xtlb/after-hours
XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform
June 30, 2026  |  quiverquant.comQ
XTL Completed the Acquisition of Psyga Bio Ltd.
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3320211/0/en/xtl-completed-the-acquisition-of-psyga-bio-ltd.html
XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026
June 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xtl-biopharmaceuticals-adjourns-extraordinary-shareholder-meeting-to-june-29-2026?utm_source=marketbeat.com&utm_medium=referral
XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq
May 23, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68578824-xtl-biopharmaceuticals-ltd-xtl-announces-receipt-of-staff-delist-determination-from-nasdaq-399.htm
XTL Announces Receipt of Staff Delist Determination from Nasdaq
May 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300353/0/en/xtl-announces-receipt-of-staff-delist-determination-from-nasdaq.html
XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xtl-biopharmaceuticals-calls-june-22-2026-meeting-to-approve-psyga-bio-acquisition-and-capital-raise?utm_source=marketbeat.com&utm_medium=referral
XTL Biopharmaceuticals Ltd ADR XTLB
May 14, 2026  |  morningstar.comM
XTL Biopharmaceuticals Delays 20-F Amid Subsidiary Liquidation
May 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XTLB/pressreleases/1657776/xtl-biopharmaceuticals-delays-20-f-amid-subsidiary-liquidation/
XTL Biopharmaceuticals Ltd.
May 1, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/xtlb/financials?countrycode=il
Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key
May 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/commodities/JEZ25/pressreleases/1598440/washington-just-opened-the-door-to-psychedelic-medicine-this-microcap-already-has-a-key/
XTLB stock surges 50%, breaches 200-DMA for first time in over 3 months – here’s what the acquisition of Psyga Bio brings to the table
May 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/xtlb-stock-surges-50-breaches-200-dma-for-first-time-in-over-3-months-here-s-what-the-acquisition-of-psyga-bio-brings-to-the-table/ar-AA2210wc
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and ...
April 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/xtl-biopharmaceuticals-to-acquire-psyga-bio-establishing-a-leading-psychedelic-biotechnology-platform-with-advanced-clinical-pipeline-licensed-gmp-manufacturing-and-proprietary-psilocybin-1036078577
XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth
April 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/xtl-biopharmaceuticals-xtlb-acquisition-of-psyga-bio-targets-psychedelic-biotech-growth/ar-AA220P8R
XTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcement
April 29, 2026  |  quiverquant.comQ
XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline
April 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xtl-biopharmaceuticals-to-acquire-psygabio-in-all-stock-deal-to-expand-psychedelic-drug-pipeline?utm_source=marketbeat.com&utm_medium=referral
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283784/0/en/xtl-biopharmaceuticals-to-acquire-psyga-bio-establishing-a-leading-psychedelic-biotechnology-platform-with-advanced-clinical-pipeline-licensed-gmp-manufacturing-and-proprietary-psi.html
XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Announces ADS Ratio Change
March 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68002842-xtl-biopharmaceuticals-ltd-xtl-biopharmaceuticals-announces-ads-ratio-change-399.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

AquaBounty Technologies stock logo

AquaBounty Technologies NASDAQ:AQB

$0.95 0.00 (-0.16%)
As of 03:59 PM Eastern

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

Cardio Diagnostics stock logo

Cardio Diagnostics NASDAQ:CDIO

$1.87 -0.08 (-3.95%)
Closing price 03:58 PM Eastern
Extended Trading
$1.87 0.00 (-0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Propanc Biopharma stock logo

Propanc Biopharma NASDAQ:PPCB

$0.53 -0.10 (-15.37%)
Closing price 04:00 PM Eastern
Extended Trading
$0.54 +0.00 (+0.86%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

XTL Biopharmaceuticals stock logo

XTL Biopharmaceuticals NASDAQ:XTLB

$2.40 +0.21 (+9.32%)
Closing price 03:54 PM Eastern
Extended Trading
$2.36 -0.04 (-1.87%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas